Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

women, with ovarian cancer stage III-IV or recurrent with carcinomatosis treated with cytoreduction and HIPEC

women, with ovarian cancer stage III-IV or recurrent with carcinomatosis, treated with systemic chemotherapy only

cytoreduction CCR 0-1, and HIPEC close technique

cytoreduction and HIPEC

Objectives:

Compare overall survival (OS) and progression-free survival (PFS) among ovarian cancer patients who underwent into cytoreduction and HIPEC procedure vs patients who only received systemic chemotherapy in a 10-years follow up of a case-control study

Methods:

Cases were defined as patients treated by cytoreduction and HIPEC, and were matched (1:2) with patients treated with chemotherapy only, defined as controls. PFS and OS in the two groups were measured and compared. PFS was calculated from initiation of treatment to progression, death or to the last known follow-up. OS was calculated from initiation of treatment to death or to the last known follow-up.

Epithelial ovarian cancer has the highest mortality of all gynecologic tumors in the world wide. Patients are diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage III to IV disease in 75%. The 10-year survival of women with advanced-stage ovarian cancer is 10% to 15% and has not improve in the past 20 years. Despite treatment with maximal cytoreductive surgery (CRS) and platinum-based chemotherapy, approximately 70% of patients with advanced-stage disease relapse within 18 months. Given this high number of recurrences, new approaches are needed to improve outcomes for these patients. Historically, peritoneal carcinomatosis represents a devastating form of cancer progression with a very poor prognosis.

Objectives:

Compare overall survival (OS) and progression-free survival (PFS) among ovarian cancer patients who underwent into cytoreduction and HIPEC procedure vs patients who only received systemic chemotherapy in a 10-years follow up of a case-control study

Methods:

Cases were defined as patients treated by cytoreduction and HIPEC, and were matched (1:2) with patients treated with chemotherapy only, defined as controls. PFS and OS in the two groups were measured and compared. PFS was calculated from initiation of treatment to progression, death or to the last known follow-up. OS was calculated from initiation of treatment to death or to the last known follow-up.

HIPEC in Ovarian Cancer, Case-Controls Study With 10-years Follow up

HIPEC in Ovarian Cancer: The First Case Control Study in Mexican Patients With 10-year Follow-up

survillance from HIPEC procedure/IV chemotherapy for carcinomatosis, to death date or last consultation (months) Kaplan Meier curve

survillance from HIPEC procedure/IV chemotherapy for carcinomatosis, to recurrence date (months) Kaplan Meier curve

histological and clinical factors associated with survival. uni and multivariate analysis (X2, Cox, U Mann-Witney)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
HIPEC in Ovarian Cancer, Case-Controls Study With 10-years Follow up	NCT04234243	Ovarian Cancer HIPEC	cytoreduction a...	18 Years - 72 Years	Instituto de Seguridad Social del Estado de Mexico y Municipios
HIPEC in Ovarian Cancer, Case-Controls Study With 10-years Follow up	NCT04234243	Ovarian Cancer HIPEC	cytoreduction a...	18 Years - 72 Years	Instituto de Seguridad Social del Estado de Mexico y Municipios

Spots Global Cancer Trial Database for cytoreduction and hipec